XC-8 is under clinical development by Valenta Pharm and currently in Phase III for Acute Upper Respiratory Tract Infections. According to GlobalData, Phase III drugs for Acute Upper Respiratory Tract Infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how XC-8’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XC-8 overview
XC-8 is under development for the treatment of dry non-productive cough associated with acute viral respiratory tract infections, acute viral upper respiratory tract infections and acute bronchitis. It is administered through oral route in the film coated tablets.
Valenta Pharm overview
Valenta Pharm (Valenta) is a pharmaceutical company that manufactures and develops innovative medicines. It produces high-quality prescription and over the counter medicines. The company’s products portfolio includes CNS, cough and cold, antihistamines, gastroenterology, women and men health, antibacterial products, hangover treatment, mycology and baby cosmetics. CNS products include phenazepam, teraligen, aminazin, hypoxen, pantocalcin, nooprin, polition. Cough and cold include ingavirin, grammidin, immucil, tigroviy. Antihistamines include aeoritin. Gastroenterology products include trimedat, exportal, orliks, antareit. Women and men health products include zydena, bio max. Antibacterial products include dioxidin, zitrolid, floracyd. Hangover treatment products include zorex. Mycology include rumycoz. Baby cosmetics include krokha. It operates in Belarus, Kyrgyzstan, Azerbaijan, Armenia, and Uzbekistan. Valenta is headquartered in Moscow, Russia.
For a complete picture of XC-8’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
